anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ample evidence indicates that bufalin (BFN), a cardiotonic steroid in Bufo toad toxin, possesses a potent anticancer activity mainly by stimulating apoptosis in cancer cells. Human red blood cells (RBCs) undergo eryptosis which contributes to a plethora of pathological conditions. No reports, however, have examined the potential toxicity of BFN to RBCs. This study aims to characterize the biochemical mechanisms governing the influence of BFN on the physiology and lifespan of RBCs. Isolated RBCs from healthy volunteers were exposed to anticancer concentrations of commercially available BFN from the skin of Bufo gargarizans (10-200 μM) for 24 h at 37 °C. Photometric assays were used to estimate hemolysis and hemolytic markers, and flow cytometry was used to detect eryptotic markers. Phosphatidylserine externalization was captured by fluorescein isothiocyante-labeled annexin V, cellular dimensions by light scatter patterns, and intracellular Ca2+ and reactive oxygen species (ROS) by fluorogenic dyes Fluo4/AM and 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA), respectively. BFN caused Ca2+-independent hemolysis and release of LDH, AST, CK, and K+, and increased annexin V-bound cells, cytosolic Ca2+, cell shrinkage, and ROS levels. BFN also disrupted Na+ and Mg2+ trafficking, and was sensitive to PEG 8000, sucrose, SB203580, and NSC 23766. In whole blood, BFN depleted hemoglobin stores, increased fragmented RBCs, and was selectively toxic to reticulocytes, lymphocytes, and platelets. In conclusion, BFN elicits premature RBC death, subject to regulation by p38 MAPK and Rac1 GTPase, and is detrimental to other peripheral blood cells. Altogether, these novel findings prompt cautious consideration of the toxin in anticancer therapy.
The purpose of this Mentored Research Scientist Development Award (K01) is to provide the candidate with the training and expertise needed to transition to research independence in the science of HIV prevention and intervention. The fastest growing HIV epidemics globally are driven by injection drug use. Central Asia has some of the highest rates of injection drug use and one of the fastest growing HIV epidemics in the world. HIV-positive people who inject drugs (PWID) face many barriers to antiretroviral therapy (ART) adherence, such as misperceptions about ART, stigma and substance use. Previous research among this population has shown that couple-based HIV interventions are highly efficacious at reducing risk behaviors, but there is currently no couple-based ART adherence intervention for PWID. The research aims of this proposal are to 1) identify core components of the SMART Couples intervention and other existing ART adherence intervention strategies and assess their appropriateness and feasibility as an integrated, couple-based ART adherence intervention for HIV+ PWID living in Kazakhstan (Phase 1); 2) adapt and refine SMART Couples and identify augmentative intervention strategies to create an integrated, couple-based ART adherence intervention for HIV+ PWID and their primary sex partners using results from Aim 1 (Phase 2); and 3a) pilot test the resulting couple-based intervention among 66 heterosexual PWID couples in Kazakhstan through a randomized control trial to assess the safety, feasibility, and acceptability of the intervention and obtain preliminary estimates of adherence outcomes in the intervention arm versus standard of care; and 3b) assess the feasibility and acceptability of conducting dried blood spot testing as part of an adherence intervention in a clinical setting (Phase 3). The proposed career development plan has been designed to augment the candidate's current training in epidemiology and enable her to 1) gain research skills in the design and adaptation of HIV interventions, with an emphasis on adherence among marginalized populations; 2) obtain methodological expertise in dyad and intensive longitudinal analysis and the triangulation of behavioral, biomedical, and technological data, particularly for the purposes of interpreting and analyzing these types of data to assess intervention efficacy and measure ART adherence; 3) acquire training in the conduct and analysis of qualitative in-depth interviews and focus groups, particularly for designing and adapting HIV interventions and assessing intervention feasibility and acceptability; and 4) increase professional skills for a successful independent research career. These training goals will be achieved through a combination of didactic courses, specialized workshops and seminars, hands-on research, and an interdisciplinary team of experts. The research findings and methodological skills to be gained from this K01 have wide applicability for disease research and high transferability across diverse research settings.
Disclosed are methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. Assays useful for diagnosis and prognosis of neoplastic disease are provided which detect the external domain of c-erbB-2, the glycoprotein gp75 and quantitate the level of gp75 in the biological fluids of mammals carrying a tumor burden.     Further disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the external domain DNA  sequence of the c-erbB-2 oncogene (the gp75 gene) or fragments thereof. Such gp75 proteins and polypeptides are useful as vaccines, therapeutically in the treatment of cancer either alone or in combination with chemotherapeutic agents.     Also disclosed are antibodies to such gp75 proteins and polypeptides which are useful diagnostically and therapeutically. Still further disclosed are test kits embodying the assays of this invention.
Aspects of the invention include compositions and methods for treatment of solid tumors with engineered or non-engineered ?d-? cells. In some embodiments, the ?d-? cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-TryD binding domain, a CD8a hinge and transmembrane domain, a costimulatory domain, a 003? signalling domain, a combination thereof, or all thereof. The CAR construct can contain an anti- GPC3 binding domain, a CD8a hinge and transmembrane domain, a costimulatory domain, a CD3? signalling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as a sIL 15 domain.
The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
The hamstring stretching exercises program will be conducted five times a week, 20 min per session, for 8 weeks. The exercises will be supervised by an experienced physiotherapist with five years of clinical experience. The intervention will be divided into two parts. The first part will include exercises with a massage foam roller. The second part will include exercises of active hamstring flexibility exercises with hip flexion mobilization and the development of the habit of correct hip flexion technique, protecting the lower spine.
Patients with Alzheimer's disease (AD) present with a variety of symptoms, including core symptoms as well as behavioral and psychological symptoms. Somatosensory neural systems are generally believed to be relatively unaffected by AD until late in the course of the disease; however, somatosensory perception in patients with AD is not yet well understood. One factor that may complicate the assessment of somatosensory perception in humans centers on individual variations in pathological and psychological backgrounds. It is therefore necessary to evaluate somatosensory perception using animal models with uniform status. In the current study, we focused on the hippocampus, the primary site of AD. We first constructed a rat model of AD model using bilateral hippocampal injections of amyloid-β peptide 1-40 and ibotenic acid; sham rats received saline injections. The Morris water maze test was used to evaluate memory impairment, and the formalin test (1 % or 4 % formalin) and upper lip von Frey test were performed to compare pain perception between AD model and sham rats. Finally, histological and immunohistochemical methods were used to evaluate tissue damage and neuronal activity, respectively, in the hippocampus. AD model rats showed bilateral hippocampal damage and had memory impairment in the Morris water maze test. Furthermore, AD model rats exhibited significantly less pain-related behavior in phase 2 (the last 50 min of the 60-minute observation) of the 4 % formalin test compared with the sham rats. However, no significant changes were observed in the von Frey test. Immunohistochemical observations of the trigeminal spinal subnucleus caudalis after 4 % formalin injection revealed significantly fewer c-Fos-immunoreactive cells in AD model rats than in sham rats, reflecting reduced neuronal activity. These results indicate that AD model rats with hippocampal damage have reduced responsiveness to persistent inflammatory chemical stimuli to the orofacial region.
This Phase II study will enroll patients into three groups. Group 1 are patients who have never been treated with bevacizumab. These patients will be randomly assigned to receive either rindopepimut/GM-CSF or KLH, each along with bevacizumab. Treatment assignment for Group 1 will be blinded. Group 2 and Group 2C patients are those who are refractory to bevacizumab (experienced recurrence or progression of glioblastoma while on bevacizumab or within 2 months of discontinuing bevacizumab). These patients will all receive rindopepimut/GM-CSF along with bevacizumab. Patients will be treated until disease progression or intolerance and all patients will be followed for survival. Patients may be treated with other therapies that are not part of the study after discontinuing treatment with the study vaccine.
Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily).
PURPOSE: A cosmetic sheet or patch is provided to effective adsorb foreign materials such as heavy metal, fine dust, and sebum and to ensure anti-cytotoxicity, anti-allergy, and sedation effect. CONSTITUTION: A cosmetic sheet or patch for removing foreign materials in skin contains kapok fiber or processed material thereof. The processed material is kapok tissue, sap, extract, freeze-dried material, hydrate, enzyme hydrate, or oxidized kapok fiber. The oxidized kapok fiber is treated with NaClO_2, NaIO_4, or mixture thereof. The kapok fiber is blended with cellulose, chitosan, silk, hydrogel, cotton, polyethylene terephthalate(PET), polyethylene(PE), layon, pulp, or porous nano fiber. A cosmetic composition for removing foreign materials in skin contains the kapok fiber or processed material thereof.
The invention relates to a traditional Chinese medicine composition for treating mammary fibroadenoma. The traditional Chinese medicine composition is prepared from the following raw medicinal materials: 8-12 g of radix bupleuri, 8-12 g of curcuma tuber, 8-12 g of green tangerine peel, 8-12 g of Sinapis alba, 13-18 g of cowherb seed, 13-18 g of Zhejiang fritillaria bulb, 10-15 g of Chinese angelica, 13-18 g of Radix Astragali, 13-18 g of Radix Codonopsis, 10-15 g of radix paeoniae rubra, 10-15 g of Fructus Forsythiae, 4-7 g of Uniflower Swisscentaury Root, 15-25 g of spatholobus stem, 10-20 g of radish seed, 10-20 g of stir-fried millet sprout, 4-7 g of banksia rose, 10-15 g of corydalis tuber, 10-15 g of toosendan fruit, 10-15 g of Cortex moutan, 10-15 g of dandelion, 8-12 g of donkey-hide gelatin and 4-7 g of licorice. The traditional Chinese medicine composition has advantages of simple preparation, wide medicinal herbs resource and low cost. By water decoction for medication, the traditional Chinese medicine composition has efficacy of activating blood circulation to dissipate blood stasis, softening hardness and dissipating binds, clearing away heat and toxic materials, invigorating blood circulation and softening hardness and reinforcing qi and nourishing blood, can be used for effectively treating mammary fibroadenoma, has definite therapeutic effect and has high cure rate. By the use of the traditional Chinese medicine composition, mammary fibroadenoma is not easy to recur. The traditional Chinese medicine composition has no toxic or side effect.
1. Tehnical Result Increase in efficiency of medicinal means.         2. Essence A method for preparation of the compounds of the formula (I) comprises interaction of the compounds of the formula (II), (III) or (IV) (provided in the specification) with OR in the presence of retention agent of hydroxide or in the case of then compound, the formula (IV), the interaction with the auxiliary base and the retention agent of hydroxide, wherein X is a group and the values of R-R4 are provided in the description.            3. Field of Application Medicine.
DERMA-SMOOTHE/FS Body Oil is for topical use only. Not for oral, ophthalmic, or intravaginal use.

Apply the least amount of DERMA-SMOOTHE/FS Body Oil needed to cover the affected areas. Discontinue use when control of disease is achieved within 2 weeks or contact the healthcare provider if no improvement is seen within 2 weeks.

Do not use on the face, axillae, or groin unless directed by the healthcare provider. Do not apply to intertriginous areas due to the increased risk of local adverse reactions [see Adverse Reactions (6) and Use in Specific Populations (8.4)].

Do not apply to the diaper area; diapers or plastic pants may constitute occlusive use [see Warnings and Precautions (5.1)].
Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity.
PURPOSE: A composition for improving hair and scalp health is provided to ensure antioxidation, anti-inflammation, and antibacterial properties and excellent cell growth. CONSTITUTION: A composition for improving hair and scalp health contains Swertia pseudochinensis Hera extract, Panax ginseng extract, and henna extract as active ingredients. The composition is a cosmetic composition for hair growth. The composition is also a cosmetic composition for relieving dandruff and scalp inflammation. The composition has antioxidation, anti-inflammation, and anti-bacterial properties and cell proliferation abilities. The composition is used in the form of a hair toner, hair lotion, hair cream, hair spray, hair mousse, hair gel, hair soap, hair shampoo, hair rinse, or hair pack.
PURPOSE:To efficiently obtain the subject compound useful as a medicine for ovary cancer, breast cancer and lung cancer, by adding coconut milk to a medium containing the cultured cells from a plant capable of producing a taxane-type diterpene to conduct a tissue culture and by taking the aimed product from the cultured product. CONSTITUTION:A solid medium spiked with naphthaleneacetic acid so as to be 10<-5>M in its concentration is inoculated with part of the stem of a plant capable of producing a taxane-type terpene (e.g. Taxus cuspidata Sieb.) to conduct static culture in a dark place at 25 deg.C to produce cultured cells or cultured tissue. The resultant medium containing such cells or tissue is incorporated with coconut milk to perform a tissue culture through shaking culture at 25'C for 14 days. Then, the resultant cultured cells or cultured tissue is taken by filtration and lyophilized and then put to extraction with e.g. methanol; the resulting liquid extract is then concentrated and subjected to high-performance liquid chromatography to carry out purification, thus affording the objective taxane-type diterpene hopeful of a medicine for ovary cancer, breast cancer and lung cancer etc. (e.g. taxol, baccatin III, cephalomannine, 10-deacetyl baccatin III).
PROBLEM TO BE SOLVED: To provide new means to study, diagnose, prevent and treat inflammation. SOLUTION: DNA sequences encoding endothelial cell-leukocyte adhesion molecules (ELAMs), methods for producing such molecules, and ELAMs (including the specific molecules ELAM1 and VLAM1 and 1b) substantially free from normally associated animal proteins are disclosed. Antibodies to ELAMs are also disclosed. DNA sequences encoding molecules (MILAs) involved in leukocyte adhesion, method for producing such molecules and MILAs (including the specific molecule, CDX) substantially free from normally associated animal proteins are also disclosed. Antibody preparations which are reactive for MILAs are also disclosed. Methods for identifying molecules which inhibit binding of leukocytes to endothelial cells, methods for inhibiting leukocyte binding to endothelial cells, and methods for detecting acute inflammation are disclosed.
PROBLEM TO BE SOLVED: To obtain a nontoxic cosmetic and/or dermatological composition capable of effectively bringing skin to light color at a low cost. SOLUTION: This composition contains 0.01-50wt.% α-hydroxy acid and 0.05-20wt.% titanium oxide based on the total amount of the composition. As the α-hydroxy acid, a 2-18C α-hydroxy alkanoic acid such as lactic acid, glycolic acid, citric acid and/or tartaric acid can be preferably used. Titanium oxide can be used as it is or as in a form of an arbitrary surface treated pigment or a fine particulate pigment. The composition is prepared into a water-in-oil type emulsion, an oil-in-water type emulsion, a micro emulsion, a serum or a vehicle dispersion by further adding 0.01-20wt.% usual adjuvant. The composition is applied to the skin of especially Negroes and Asians.
In the first 3-patient cohort, the dose of lacosamide given is 50mg/d BID. Enrollment to the next higher dose cohort will be initiated only if none of the 3 participants exhibits a DLT in the 21 ±3 days following completion of the 7 day drug therapy. Dose escalation will proceed according to the Bayesian optimal interval (BOIN) design at incremental increase of 100mg/day in two divided doses. The maximum daily dose of lacosamide will be 400mg/day.
Epidemiological studies show a very rapid increase in the epidemic of obesity in the Caribbean population. The latest prevalence data in Martinique show that 6 out of 10 adults are overweight and 1 out of 4 is obese (Body Mass Index, BMI ≥ 30 kg/m2). Obesity with a BMI ≥ 35 kg/m2 is said to be "morbid" because of its association with numerous cardiovascular comorbidities. A balanced diet and physical activity are effective behavioural modalities for weight loss, which, even at low intensity, can reduce cardiovascular complications and the risk of death. However, many patients do not adhere to these constraints over a long period of time and about 50% of them regain weight after the first year. These observations highlight the value of alternative therapies with lasting effects on weight loss and the cardio-metabolic comorbidities of obesity.

Bariatric surgery with vertical calibrated vertical gastroplasty with gastric resection (or sleeve gastrectomy) and Roux-en-Y gastric bypass are therapeutic options that are not only effective in the long term for weight loss but also beneficial in terms of insulin resistance and cardiovascular complications. Bariatric surgery is currently indicated for the treatment of morbid obesity with a BMI ≥ 40 kg/m2 or a BMI ≥ 35 kg/m2 in the presence of complications. Some patients nevertheless remain resistant to the beneficial cardio-metabolic effects of bariatric surgery. The reasons for this resistance are attributed to factors such as age \> 60 years, female sex, BMI \> 45 kg/m2, African-American or Hispanic origin, and history of type 2 diabetes. Regardless of these factors, several studies have pointed out that a chronic low-grade inflammatory state reduces the magnitude of weight loss and thus counters the beneficial cardio-metabolic effects of bariatric surgery.

Visceral adipose tissue is largely responsible for the inflammatory syndrome in obese patients, via the activation of nuclear transcription factors (NFkB, in particular) that stimulate the synthesis of numerous mediators and pro-inflammatory cytokines. Obesity can also induce the formation of multi-protein platforms called inflammasomes, including the active assembly of inflammatory caspases (caspase-1, in particular) that cleave the pro-interleukins IL1β and IL18 into mature pro-inflammatory cytokines IL1β and IL18. The role of the inflammasome NLRP3 ("NOD-like receptor family, pyrin domain containing 3") in the inflammatory response has been particularly studied in humans due to its association with multiple chronic inflammatory, infectious and cardio-metabolic pathologies. Among the biomolecules responsible for activation of the NLRP3 inflammasome during obesity are palmitate, sphingolipids and cholesterol crystals. The NLRP3 inflammasome is also activated by mitochondrial production of reactive oxygen species (ROS) and by mitochondrial DNA released from mitochondria damaged by lipo-toxicity phenomena associated with obesity. More generally, the mitochondrial dysfunction of the metabolic syndrome is considered to be the causal intracellular event of the deregulation of the inflammatory response mediated by the inflammasome.
PURPOSE OF REVIEW: The purpose of this review is to highlight the most recent literature and guidelines regarding perioperative methadone and buprenorphine use.
RECENT FINDINGS: Surgical patients taking methadone and buprenorphine are being encountered more frequently in the perioperative period, and providers are becoming more familiar with their pharmacologic properties, benefits as well as precautions. Recommendations pertaining to buprenorphine therapy in the perioperative settings have changed in recent years, owing to more clinical and basic science research. In addition to their use in chronic pain and opioid use disorders, they can also be initiated for acute postoperative pain indications, in select patients and situations. Methadone and buprenorphine are being more commonly prescribed for pain management and opioid use disorder, and their continuation during the perioperative period is generally recommended, to reduce the risk of opioid withdrawal, relapse, or inadequately controlled pain. Additionally, both may be initiated safely and effectively for acute pain management during and after the operating room period.